Ua wehe ʻia ka TIL Therapy: Ke ʻimi nei i ke ʻano o ka Immunotherapy Cancer

ʻO ka lāʻau lapaʻau TILs e pili ana i ka unuhi ʻana i nā lymphocytes tumor-infiltrating (TILs), ʻo ia nā pūnaewele pale kūlohelohe anti-tumor pololei loa i loko o ke kino o ka mea maʻi, mai kahi puʻupuʻu a hoʻoulu iā lākou i nā helu he nui i loko o kahi lab. A laila hoʻokomo hou ʻia kēia mau TIL i hoʻāla ʻia i loko o ke kino o ka mea maʻi e hoʻoikaika i ka hiki o ka ʻōnaehana pale e kuhikuhi a pepehi i nā cell cancer. Hana nā TIL ma ka ʻike ʻana i nā māka kikoʻī ma nā cell cancer a me ka hoʻomaka ʻana i kahi pane pale kūʻē iā lākou, a i ka hopena e alakaʻi ai i ka luku ʻia ʻana o ka puʻupuʻu.

Ma muli o kā mākou mau hopena lapaʻau lapaʻau, ʻo ka pono holoʻokoʻa o ka monotherapy TILs e hiki aku i ka 40%, e lilo ia i ke ʻano lapaʻau tumor maikaʻi loa ma waho aʻe o ke ʻoki ʻana i loaʻa i kēia manawa. Hoʻopilikino ʻo Bioocus i kahi hoʻolālā lapaʻau piha no kēlā me kēia maʻi pākahi. E hui pū ʻia kekahi a i ʻole kekahi mau therapies me ka Tils therapy, kahi e hoʻonui ai i ka helu kūpono holoʻokoʻa i ʻoi aku ma mua o 80%. Manaʻo ka therapy hui pū ʻia e hōʻemi i ka ukana tumor i ka wā pōkole, a hāʻawi ʻo tils i kahi manawa kūpono no ka mea maʻi e loaʻa ai ka lāʻau i ka wā lōʻihi.

Kūlana kiʻekiʻe: nā pūnaewele T kikoʻī i hoʻonui ʻia e nā antigens tumor, i ʻike ʻia e nā TCR he nui

Ka tropism ikaika: ka hōʻike kiʻekiʻe o nā mea loaʻa chemokine, ka tropism tumor ikaika, a me ka hana wikiwiki

Ke pepehi ʻana i nā puʻupuʻu: Hoʻāla ʻia a hoʻonui ʻia nā TIL i 109-1011, a ua hoʻomaʻemaʻe ʻia nā koena kanesa ma hope o ke ʻoki ʻana

Ka hopena mau: Kiʻekiʻe ka hapa o nā pūnaewele hoʻomanaʻo T, a hiki iā lākou ke ola i loko o ke kino no ka manawa lōʻihi a ke nānā mau ʻia nei.

Palekana kiʻekiʻe: ka unuhi ʻana, ka hoʻonui ʻana, ka ʻole o ka hopena hōʻole, a me ka SAE o nā pūnaewele TILs mai nā maʻi ponoʻī

Ua hōʻoia ʻia ka hopena o ka lāʻau lapaʻau Tils i NSCLC (ka maʻi ʻaʻai māmā ʻaʻole liʻiliʻi),Melanoma, Ka maʻi ʻaʻai umauma, Ka maʻi ʻaʻai o ka ʻōpū, a me ke Kanesa ʻŌpū. 

Ma waho aʻe o ke ʻoki ʻana i ka puʻupuʻu mua, hiki ke hoʻāʻo ʻia no ka unuhi ʻana i nā ʻiʻo puʻupuʻu superficial, nā lymph nodes, ka pleural effusion, ascites, a me nā mea ʻē aʻe. Penei ka helu o ka pono: ka lesion mua ≥ ka metastatic lesion ≥ nā lymph nodes ≥ ascites.

ʻO kā mākou hana mahiʻai TILs i hoʻomohala kūʻokoʻa ʻia e loaʻa ai ka holomua o ≥85%. Me kahi hāpana ʻiʻo maʻamau o ≥1cm3, hiki ke mahi ʻia nā piliona o TILs, a hōʻike nā cell i ka hana cytotoxic ikaika.

1. ʻO nā TIL nā pūnaewele ponoʻī o ka mea maʻi, no laila ʻaʻohe pilikia o ka hōʻole ʻia, e hōʻoiaʻiʻo ana i ka palekana kiʻekiʻe.

2. Nā hopena ʻino: He mea maʻamau ke kuni (ma muli o ka hoʻokuʻu ʻia ʻana o nā cytokines i ka wā o ka hoʻomaʻemaʻe ʻana o ka TILs cell-mediated tumor, e hoʻoulu ai i ke kuni pōkole, ʻaʻole pono ka lāʻau lapaʻau kikoʻī a hoʻopau ʻia ma kāna iho).

3. ʻO nā hopena ʻino ʻē aʻe i hōʻike ʻia i nā haʻawina e pili ana i ka thrombocytopenia, febrile neutropenia, hypertension, a me nā mea ʻē aʻe, ʻo ka hapa nui i pili i nā TIL i hui pū ʻia me nā lāʻau ʻē aʻe e like me ka chemotherapy pre-treatment (cyclophosphamide + fluorouracil), IL-2 kiʻekiʻe, PD-1 monoclonal antibodies, a me nā mea ʻē aʻe.